|
[1] Yoshikawa H, Tasaka K.Suppression of mast cell activation by glucocorticoid[J].Arch Immunol Ther Exp (Wars2) , 2000, 48∶487-495.
|
|
[2]Shimizu S, Satomura K, Aramaki T, et al.Hepatic chymase level in chronic hepatitis and co-localizaition of chymase with fibrosis[J].Hepatol Res, 2003, 27∶57-61.
|
|
[3]Johnson PJ, Mcfarlan IJ.Meeting report:International autoimmune hepatitis group[J].Hepatology, 1993, 18:998-1005.
|
|
[4]Satomura K, Shimizu S, Nagato T, et al.Establishiment of an assay method for human mast cell chymase[J].Hepatol Res, 2002, 24:361-367.
|
|
[5]Yoshikawa H, Tasaka K.Suppression of mast cell activation by glucocorticoid[J].Arch Immunol Ther Exp (Wars2) , 2000, 48:487-495.
|
|
[6]Ginsburg H, Ben-David E.Mast cell growth on fibroblast monolayers:two-cell entities[J].Immunology, 1998, 45:371-380.
|
|
[7]Farrell DJ, Hines JE, Walls AF, et al.Intrahepatic mast cells in chronic liver disease[J].Hepatology, 1995, 22:1175-1181.
|
|
[8] Tani K, Ogushi F, Kawano T, et al.Chymase is apotent chemoattractant for human monocytes an neutrophils[J].Jleukoc Biol, 2000, 67:585-589.
|